{"organizations": [], "uuid": "5592c50a79f0e279ec54c5421546c9859480e321", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/8", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/02/27/globe-newswire-editas-medicine-to-host-conference-call-discussing-fourth-quarter-and-full-year-2017-corporate-update-and-results.html", "country": "US", "domain_rank": 767, "title": "Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-28T00:01:00.000+02:00", "replies_count": 0, "uuid": "5592c50a79f0e279ec54c5421546c9859480e321"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/02/27/globe-newswire-editas-medicine-to-host-conference-call-discussing-fourth-quarter-and-full-year-2017-corporate-update-and-results.html", "ord_in_thread": 0, "title": "Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2017 Corporate Update and Results", "locations": [], "entities": {"persons": [{"name": "cristi barnett", "sentiment": "none"}], "locations": [{"name": "mass.", "sentiment": "none"}, {"name": "cambridge", "sentiment": "none"}], "organizations": [{"name": "editas medicine, inc.", "sentiment": "neutral"}, {"name": "editas medicine", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "CAMBRIDGE, Mass., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it and webcast on Tuesday, March 6th, 2018, at 5:00 p.m. ET to discuss a corporate update and results for the fourth quarter and full year of 2017.\nTo access the call, please dial 844-348-3801 (domestic) or 213-358-0955 (international) and provide the passcode 2449529. A live webcast of the presentation will be available on the Investors & Media section of the Editas website.\nAbout Editas Medicine\nAs a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cpf1 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com .\nContacts\nMedia:\nCristi Barnett\n(617) 401-0113\ncristi.barnett@editasmed.com\nInvestors:\nMark Mullikin\n(617) 401-9083\nmark.mullikin@editasmed.com\nSource:Editas Medicine, Inc.", "external_links": ["https://www.globenewswire.com/NewsRoom/AttachmentNg/03686b66-5cbc-40b5-9dfa-be0e7858ac97", "https://www.globenewswire.com/Tracker?data=RCOdUzKtjL-ZS1pXn9l8EUeqBjvYF62lXIWRolMKEx4ydn4x1-hurKQnrovA44pYoW5gNuEYCWJ3QeVxLAebQKqEtBWhY7W3u_leCWIO0xA="], "published": "2018-02-28T00:01:00.000+02:00", "crawled": "2018-02-28T01:43:00.000+02:00", "highlightTitle": ""}